GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications
American Journal of Hypertension · 01.05.2026 · 39 (5) · 611-622
DOI: 10.1093/ajh/hpaf205 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hypertension, online erschienen am 23.10.2025. Verfasst von Areesha Moiz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Blood Pressure, Hypertension, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fond de recherche du Québec-Santé, McGill University.
Abstract (Originalsprache)
Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for the treatment of type 2 diabetes and, more recently, for weight management among individuals without diabetes.
Aim
This review synthesizes the current evidence on the mechanisms by which GLP-1 RAs affect BP, their clinical effects across populations, and the implications for patient care. We discuss subpopulations who may benefit from their BP-lowering effects, identify limitations in the existing evidence, and explore future directions for research.
Results
Beyond their metabolic effects, growing evidence suggests that GLP-1 RAs produce modest reductions in BP, typically 2-5 mm Hg systolic, across diverse populations with diabetes, obesity, or at high cardiovascular risk. These reductions appear to be driven primarily by weight loss, with additional contributions from potential weight-independent mechanisms such as natriuresis, improved endothelial function, and attenuation of vascular inflammation. Although smaller in magnitude than those achieved with traditional antihypertensive drugs, the BP-lowering effects of GLP-1 RAs can translate into meaningful cardiovascular risk reduction at the population level and provide additive BP benefit when used alongside conventional therapies. Among individuals with hypertension, GLP-1 RAs are generally well tolerated, although small increases in heart rate and potential interactions with volume-regulating medications may warrant clinical attention.
Conclusion
As newer GLP-based therapies continue to emerge, a clearer understanding of their effects on BP may inform more integrated approaches to cardiometabolic care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, QC, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
- Department of Medicine, McGill University, Montreal, QC, Canada.
- Faculty of Medicine, McGill University, Montreal, QC, Canada.
- Division of Cardiology, Jewish General Hospital/McGill University, Montreal, QC, Canada.
Förderung
- Fond de recherche du Québec-Santé
- McGill University
Zitieren
APA
Moiz, A., Zolotarova, T., Filion, K. B., & Eisenberg, M. J. (2026). GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications. American Journal of Hypertension, 39(5), 611-622. https://doi.org/10.1093/ajh/hpaf205
Vancouver
Moiz A, Zolotarova T, Filion KB, Eisenberg MJ. GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications. American Journal of Hypertension. 2026;39(5):611-622. doi:10.1093/ajh/hpaf205
BibTeX
@article{Moiz2026,
author = {Moiz, Areesha and Zolotarova, Tetiana and Filion, Kristian B and Eisenberg, Mark J},
title = {GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications},
journal = {American Journal of Hypertension},
year = {2026},
volume = {39},
number = {5},
pages = {611--622},
doi = {10.1093/ajh/hpaf205}
}
EUVIMED